(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Brazil expands pesticide packaging reverse logistics - 2German men need approval for stays abroad under military service law
- 3South Korea president says Iran war shows the need to ditch ‘extremely risky’ fossil fuels
- 4The Main 15 Applications for Efficiency and Association
- 5Health officials report 14 Legionnaires' disease cases in Florida, gym connection suspected
- Pick Your #1 breakfast food
- Fundamental Home Machines: An Easy to understand Determination Guide
- With more Moon missions on the horizon, avoiding crowding and collisions will be a growing challenge
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- The Most Enrapturing Authentic Milestones to Visit
- Study casts doubt on potential for life on Jupiter's moon Europa
- Figure out How to Track the Establishment of New 5G Pinnacles
- Deaths reported in Lebanon as Israel and Hezbollah exchange attacks
- Step by step instructions to Protect Your Retirement with Senior Protection.
